COVID-19 Post-Vaccination Observation

COVID-19 Post-Vaccination Observation on Immune Exhaustion

The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis. The study continued to the third-dose full vaccination of the participant with the recombined COVID-19 vaccination and afterwards. The study completed until intervention.

Study Overview

• Status: Active, not recruiting
• Conditions: Immune System Diseases; Immune System Disorder; COVID-19 Vaccine Adverse Reaction

• Study Type: Observational
• Enrollment (Actual): 1

Contacts and Locations

Study Locations

• China
  • Chongqing
    • Chongqing, Chongqing, China, 402762
      • Residential Address

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

The study population is currently focused on Asians.

Description

All COVID-19 vaccinated are eligible for inclusion.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Immune Disorder

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Chemiluminescent Immunoassay for Human Immunodeficiency Virus	7 months
Carcinoembryonic Antigen	7 months
Alpha Fetoprotein	7 months
Carbohydrate Antigen 19-9	7 months
Mucin-16	7 months
Cancer Antigen 15-3	7 months
Prostate-Specific Antigen	7 months
Leukocytes	7 months
Leukocyte Percentage	7 months
Cholesterol	7 months

Collaborators and Investigators

• Sponsor: Yang I. Pachankis, PhD

Publications and helpful links

General Publications

• Pachankis YI. Questions of COVID-19: Institutional Derogations of Global Health. Lambert Academic Publishing. 2023. ISBN: 978-6206153849.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2021
• Primary Completion (Actual): January 4, 2023
• Study Completion (Estimated): December 24, 2023

Study Registration Dates

• First Submitted: October 26, 2023
• First Submitted That Met QC Criteria: October 26, 2023
• First Posted (Actual): October 30, 2023

Study Record Updates

• Last Update Posted (Actual): October 30, 2023
• Last Update Submitted That Met QC Criteria: October 26, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Immune System Diseases
• Other Study ID Numbers: SARS-Immune-00

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Sharing Time Frame: The data will be available upon completion and will be kept for as long as the repository is available.
• IPD Sharing Supporting Information Type: CSR

Study Data/Documents

1. Individual Participant Data Set
   Information identifier: 10.17605/OSF.IO/2MGJK

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No